Clinical trials: Refractory Transformed Follicular Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma

Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

• Completed
• Age: 18 years and older
• Early Phase 1

This pilot clinical trial studies how well buparlisib works in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment.

Conditions

Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma

Trial name

NCT01719250

Testing

Buparlisib, Laboratory Biomarker Analysis, Questionnaire Administration

Where

United States

Volunteers

7 people

Sponsor

Mayo Clinic